01525nas a2200421   4500000000100000008004100001260001300042653001200055653002600067653002600093653001900119653001600138653002800154653001200182653003100194653003000225653002100255653001100276653002300287653001200310653000900322653000900331653002400340653001500364653001600379653002500395653001400420653001300434100001500447700001800462700001500480245009500495856004100590300001000631490000700641520044100648022001401089       2000                            d  c2000 Dec10aAnimals10aAnti-Infective Agents10aAntitubercular Agents10aClarithromycin10aClofazimine10aColony Count, Microbial10aDapsone10aDrug Resistance, Microbial10aDrug Resistance, Multiple10aFluoroquinolones10aHumans10aLeprostatic Agents10aleprosy10aMale10aMice10aMice, Inbred BALB C10aMice, Nude10aMiddle Aged10aMycobacterium leprae10aOfloxacin10aRifampin1 aMatsuoka M1 aKashiwabara Y1 aNamisato M00aA Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.  uhttp://ila.ilsl.br/pdfs/v68n4a07.pdf  a452-50 v683 a<p>Mycobacterium leprae were isolated from a Japanese patient, and susceptibility to antileprosy drugs was examined by the mouse foot pad method. The isolate was susceptible to clofazimine and clarithromycin, and resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Mutations were identified in the genes associated with resistance to these drugs. The risk of the emergence of leprosy with multidrug resistance is emphasized.</p>  a0148-916X